What's in SUMITOMO PHARMA AM's pipeline?

SUMITOMO PHARMA AM has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with SUMITOMO PHARMA AM's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sumitomo-pharma-am.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

SUMITOMO PHARMA AM — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SUMITOMO PHARMA AM pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Eslicarbazepine Acetate	ESLICARBAZEPINE	marketed			Neuroscience	2023-01-01
Aptiom	ESLICARBAZEPINE ACETATE	marketed	eslicarbazepine acetate	Sodium channel alpha subunit	Neuroscience	2013-01-01

Therapeutic area mix

Neuroscience · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for SUMITOMO PHARMA AM:

Cite this brief

Drug Landscape (2026). SUMITOMO PHARMA AM — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sumitomo-pharma-am. Accessed 2026-05-17.